| First Author | Heinhuis B | Year | 2011 |
| Journal | Proc Natl Acad Sci U S A | Volume | 108 |
| Issue | 12 | Pages | 4962-7 |
| PubMed ID | 21383200 | Mgi Jnum | J:170086 |
| Mgi Id | MGI:4943987 | Doi | 10.1073/pnas.1016005108 |
| Citation | Heinhuis B, et al. (2011) Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis. Proc Natl Acad Sci U S A 108(12):4962-7 |
| abstractText | Different splice variants of the proinflammatory cytokine IL-32 are found in various tissues; their putative differences in biological function remain unknown. In the present study, we report that IL-32gamma is the most active isoform of the cytokine. Splicing to one less active IL-32beta appears to be a salvage mechanism to reduce inflammation. Adenoviral overexpression of IL-32gamma (AdIL-32gamma) resulted in exclusion of the IL-32gamma-specific exon in vitro as well as in vivo, primarily leading to expression of IL-32beta mRNA and protein. Splicing of the IL-32gamma-specific exon was prevented by single-nucleotide mutation, which blocked recognition of the splice site by the spliceosome. Overexpression of splice-resistant IL-32gamma in THP1 cells or rheumatoid arthritis (RA) synovial fibroblasts resulted in a greater induction of proinflammatory cytokines such as IL-1beta, compared with IL-32beta. Intraarticular introduction of IL-32gamma in mice resulted in joint inflammation and induction of several mediators associated with joint destruction. In RA synovial fibroblasts, overexpression of primarily IL-32beta showed minimal secretion and reduced cytokine production. In contrast, overexpression of splice-resistant IL-32gamma in RA synovial fibroblasts exhibited marked secretion of IL-32gamma. In RA, we observed increased IL-32gamma expression compared with osteoarthritis synovial tissue. Furthermore, expression of TNFalpha and IL-6 correlated significantly with IL-32gamma expression in RA, whereas this was not observed for IL-32beta. These data reveal that naturally occurring IL-32gamma can be spliced into IL-32beta, which is a less potent proinflammatory mediator. Splicing of IL-32gamma into IL-32beta is a safety switch in controlling the effects of IL-32gamma and thereby reduces chronic inflammation. |
